Exhibit 99.1 https://files.reportify.cc/media/production/BNTXddcf2ca2a8b2317ecc8b6088b8b48208.jpg BioNTech SE Quarterly Report of BioNTech SE for the three and nine months ended September 30, 2024 A C T I N G T O G E T H E R — C R E A T I N G S Y N E R G I E S Exhibit 99.1 Our principal executive offices are located at An der Goldgrube 12, D-55131 Mainz, Germany. Our telephone number is +49 6131-9084-0. Our website address is www.biontech.com. The information contained on, or that can be accessed through, o ...

Presented clinical data for multiple assets across modalities, including bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine candidate BNT113 based on BioNTech's FixVac platform Initiated two Phase 2 dose optimization trials with BNT327/PM8002 in small-cell lung cancer and in triple-negative breast cancer to inform planned pivotal Phase 3 trials Phase 2 clinical trial on track to evaluate mRNA-based individualized cancer vaccine candidate autogene cevumeran (BNT122/RO7198457) as an adjuvant ...

MAINZ, Germany, October 31, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), will host an edition of the Company’s Innovation Series R&D Day at 10:30 a.m. Eastern Standard Time (16:30 p.m. CET) on Thursday, November 14, 2024 in New York City, U.S. On the day, BioNTech’s leadership team will provide an overview of the Company’s corporate strategy and clinical progress across its pipeline. Investors, analysts and the interested public are invited to join the event online via t ...

We expect BioNTech SE (BNTX) to surpass expectations when it reports third-quarter 2024 results on Nov. 4, before the opening bell.Let’s see how things have shaped up for the quarter to be reported.Factors at PlayBioNTech’s top line currently includes sales from its mRNA-based COVID-19 vaccine, Comirnaty, developed in partnership with Pfizer (PFE) . The vaccine is approved in several countries and has been a key contributor to BioNTech’s top line. The Zacks Consensus Estimate for revenues stands at $651.8 m ...

I'm a biotech and healthcare investment analyst with several years of clinical experience and a Master of Business Administration. I've had the privilege of sharing my analyses on Seeking Alpha since 2017. Outside of spending time with family, this is my favorite thing to do. I utilize risk-return charts and DCF analyses to highlight investment opportunities and risks. I'm a big fan of the barbell strategy: 90% in safe assets like Treasuries and ETFs, and 10% in high-growth stocks—keeping risk management fr ...

MAINZ, Germany, October 21, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2024 on Monday, November 4, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this link. O ...

BioNTech SE (NASDAQ:BNTX) Company Conference Call October 1, 2024 9:00 AM ET Company Participants Karim Beguir - Chief Executive Officer, InstaDeep Uğur Şahin - Chief Executive Officer, BioNTech Ryan Richardson - Chief Strategy Officer, BioNTech Nacef Labidi - Head of Infrastructure, InstaDeep Alex Laterre - Head of Research, InstaDeep Alex Graves - Research Scientist, InstaDeep Bora Guloglu - Research Scientist, InstaDeep Julia Gimbernat - Product Manager, InstaDeep Arnu Pretorius - Research Scientist, In ...

Core Insights - BioNTech is advancing its strategy to integrate artificial intelligence (AI) across its immunotherapy pipeline, aiming to enhance personalized medicine and targeted therapies [2][3] - The company has introduced a new near exascale supercomputer, Kyber, to support large-scale computations necessary for its AI initiatives [1][3] - BioNTech has unveiled novel AI Bayesian Flow Network (BFN) models for protein sequence generation, which are expected to significantly contribute to its drug development processes [1][2] AI Integration and Development - BioNTech, in collaboration with its AI subsidiary InstaDeep, is leveraging AI to develop personalized vaccines and therapies, showcasing its commitment to innovation in individualized medicine [2][3] - The DeepChain™ multiomics design platform has been successfully applied to various projects and is now open for external partnerships, indicating a strategic move towards collaboration in AI and biotechnology [3] Technological Advancements - The deployment of AI across BioNTech's immunotherapy pipeline includes advancements in immunohistochemistry, DNA/RNA sequencing, proteomics, protein design, and lab functional validation [1] - The introduction of the BFN generative protein model is a key technological advancement that aims to unlock new potentials in vaccine and cancer treatment development [2][3]

Core Insights - BioNTech SE, in collaboration with its AI company InstaDeep Ltd., will host an AI Day on October 1, 2024, in London to showcase their AI strategy and capabilities [1] - The event will focus on the application of AI in BioNTech's pipeline and internal processes [1] Company Overview - BioNTech is a global next-generation immunotherapy company that develops novel therapies for cancer and other serious diseases [3] - The company utilizes a variety of computational discovery and therapeutic drug platforms for rapid biopharmaceutical development [3] - BioNTech's oncology product portfolio includes individualized and off-the-shelf mRNA-based therapies, CAR T cells, protein-based therapeutics, and small molecules [3] - The company is also developing multiple mRNA vaccine candidates for infectious diseases alongside its oncology pipeline [3] - BioNTech has established partnerships with various global pharmaceutical collaborators, including Pfizer and Genentech [3]

BioNTech SE Sponsored ADR (BNTX) shares soared 5.8% in the last trading session to close at $105. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 17% gain over the past four weeks. Last month, the FDA approved the company's updated mRNA-based COVID-19 vaccine that targets the KP.2 strain of the virus. The vaccine has been developed in partnership with Pfizer. The regulatory body approved Pfizer/BioNTech's Comirnaty for use in ind ...